Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
Oculis (Nasdaq: OCS) and EURETINA awarded the Ramin Tadayoni Award 2025 to Dr. Prithvi Ramtohul for retina research.
The award, established in 2024 to honor Professor Ramin Tadayoni, supports postgraduate retinal research and recognizes Dr. Ramtohul's work on retinal imaging, including studies of retinal ganglion cell plasticity and multimodal imaging findings such as BALAD and ASHH. Oculis reiterated its collaboration with EURETINA and commitment to advancing retinal science through this annual prize.
Oculis (Nasdaq: OCS) e EURETINA hanno conferito il Ramin Tadayoni Award 2025 al Dr. Prithvi Ramtohul per la ricerca sulla retina.
L award, istituito nel 2024 per onorare il professor Ramin Tadayoni, sostiene la ricerca retinica post laurea e riconosce il lavoro del Dr. Ramtohul sull'imaging della retina, inclusi gli studi sulla plasticità delle cellule ganglionari della retina e i riscontri di imaging multimodale come BALAD e ASHH. Oculis ha ribadito la sua collaborazione con EURETINA e l'impegno a far progredire la scienza retinica tramite questo premio annuale.
Oculis (Nasdaq: OCS) y EURETINA otorgaron el Ramin Tadayoni Award 2025 al Dr. Prithvi Ramtohul por su investigación retiniana.
El premio, establecido en 2024 para honrar al profesor Ramin Tadayoni, apoya la investigación retinal de posgrado y reconoce el trabajo del Dr. Ramtohul sobre imágenes de la retina, incluidas las studies sobre la plasticidad de las células ganglionares de la retina y hallazgos de imagen multimodal como BALAD y ASHH. Oculis reiteró su colaboración con EURETINA y su compromiso de avanzar la ciencia retiniana a través de este premio anual.
Oculis (Nasdaq: OCS)와 EURETINA는 망막 연구를 위해 Ramin Tadayoni Award 2025를 Dr. Prithvi Ramtohul에게 수여했습니다.
이 상은 2024년 교수 Ramin Tadayoni를 기리기 위해 설립되었으며, 포스트그래듀이트 망막 연구를 지원하고 망막 이미지 연구에서 Dr. Ramtohul의 연구—망막 신경절세포 가소성 연구 및 BALAD 및 ASHH와 같은 다중 모달 영상 소견 포함—을 인정합니다. Oculis는 EURETINA와의 협력을 재확인하고 매년 이 상을 통해 망막 과학을 발전시키려는 약속을 재확인했습니다.
Oculis (Nasdaq: OCS) et EURETINA ont décerner le Ramin Tadayoni Award 2025 au Dr Prithvi Ramtohul pour la recherche sur la rétine.
Le prix, créé en 2024 pour honorer le professeur Ramin Tadayoni, soutient la recherche rétinienne de troisième cycle et reconnaît les travaux du Dr Ramtohul sur l'imagerie de la rétine, y compris des études sur la plasticité des cellules ganglionnaires et des résultats d'imagerie multimodale tels que BALAD et ASHH. Oculis a réitéré sa collaboration avec EURETINA et son engagement à faire progresser la science rétinienne à travers ce prix annuel.
Oculis (Nasdaq: OCS) und EURETINA verleihen dem Ramin Tadayoni Award 2025 an Dr. Prithvi Ramtohul für die Retina-Forschung.
Der Preis, der 2024 zu Ehren von Professor Ramin Tadayoni ins Leben gerufen wurde, unterstützt die postgraduale Retina-Forschung und würdigt die Arbeit von Dr. Ramtohul zur Netzhautimaging, einschließlich Studien zur Plastizität der retinalen Ganglienzellen und multimodalen Bildgebungsbefunden wie BALAD und ASHH. Oculis bekräftigte seine Zusammenarbeit mit EURETINA und das Engagement, die Retina-Wissenschaft durch diesen jährlichen Preis voranzutreiben.
أوكولس (Nasdaq: OCS) و EURETINA منحا جائزة رامين تادايوني 2025 للدكتور براثفي رامتوخول لأبحاث الشبكية.
تم إنشاء الجائزة في 2024 لتكريم الأستاذ رامين تادايوني، وتدعم أبحاث الشبكية العليا وتُشيد بعمل الدكتور رامتوخول في تصوير الشبكية، بما في ذلك دراسات لمرونة خلايا العقدة الشبكية ونتائج التصوير متعدد الوسائط مثل BALAD و ASHH. أكدت أوكولس مرة أخرى تعاونها مع EURETINA والتزامها بدفع علم الشبكية إلى الأمام من خلال هذه الجائزة السنوية.
- None.
- None.
ZUG, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced, in collaboration with EURETINA, the winner of the Ramin Tadayoni Award 2025.
The Ramin Tadayoni Award honors the next generation of ophthalmologists by supporting an exceptional postgraduate scholar in retina research. It was established in 2024 in memory of the late Professor Ramin Tadayoni, Oculis’ former Chief Scientific Officer and a globally renowned leader in retinal science.
This year’s award recognizes Prithvi Ramtohul, M.D., for his significant contributions to the field of retinal imaging and diseases, and he is currently studying the long-lasting plasticity of intrinsic neuronal excitability in retinal ganglion cells.
Anat Loewenstein, M.D., President of EURETINA, said: “On behalf of EURETINA, I would like to express my gratitude to all the applicants. The standard and scope of entries submitted were remarkable, and we are delighted to recognize Dr. Ramtohul as our 2025 award recipient, who carries forward this honorable tribute. With his retinal research project, Dr. Ramtohul aims to advance our understanding of the cellular mechanisms underlying amblyopia and inform the development of targeted therapeutic interventions to improve patient outcomes. I would like to sincerely thank the review committee members and all parties involved for their contribution to this award.”
Riad Sherif, M.D., Chief Executive Officer of Oculis, said: “It is our privilege to collaborate with EURETINA on the Ramin Tadayoni Award, and we extend our congratulations to our distinguished 2025 winner, Dr. Ramtohul. Through our ongoing commitment to this award and dedication to excellence in retinal research, we continue to celebrate the remarkable legacy of Professor Ramin Tadayoni, whom we deeply valued as both a friend and colleague.”
Dr. Prithvi Ramtohul is an attending physician in the Retinal Division at Aix-Marseille University Hospital, North, France, and a Ph.D. candidate at the Ion Channel and Synapse Neurobiology Unit, INSERM-AMU, Marseille, France. Following his ophthalmology residency at Aix-Marseille University and fellowship training with Professor Ramin Tadayoni at Hospital Lariboisière, Paris, he completed a prestigious research fellowship with Professor K. Bailey Freund at the Vitreous Retina Macula Consultants of New York. Dr. Ramtohul has made significant contributions to retinal imaging and diseases through his 111 peer-reviewed publications, particularly as first author on groundbreaking studies describing novel OCT signs such as bacillary layer detachment (BALAD) and the angular sign of Henle fiber layer hyperreflectivity (ASHH), as well as newly identified retinal conditions including Stellate Multiform Amelanotic Choroidopathy (SMACH) and Multizonal Outer Retinopathy and Retinal Pigment Epitheliopathy (MORR). His research focuses on enhancing the understanding of retinal disease pathophysiology through the analysis of multimodal imaging. His contributions have been recognized with prestigious awards, including the Gabriel Coscas Award from the French Retina Society, as well as invitations to speak at 73 national and international conferences.
About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs. Oculis’ highly differentiated late-stage clinical pipeline includes three core product candidates: OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema; Privosegtor (OCS-05), a neuroprotective candidate in Phase 2 for acute optic neuritis, with potentially broad clinical applications in various neuro-ophthalmic and neurological diseases; and Licaminlimab (OCS-02), a novel topical anti-TNFα in Phase 2, being developed with a genotype-based approach to drive personalized medicine in dry eye disease. Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.
For more information, please visit: www.oculis.com
Oculis Contacts
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com
Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
oculis@icrhealthcare.com
FAQ
Who won the Ramin Tadayoni Award 2025 announced by Oculis and EURETINA?
When was the Ramin Tadayoni Award 2025 announced by Oculis?
What is the purpose of the Ramin Tadayoni Award supported by Oculis (OCS)?
What research does Dr. Prithvi Ramtohul focus on that led to the Oculis award?
How does Oculis describe its role with EURETINA in the Ramin Tadayoni Award?
